Cited by 478Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

Kastelein, John J.P., van der Steeg, Wim A., Holme, Ingar, Gaffney, Michael, Cater, Nilo B., Barter, Philip, Deedwania, Prakash, Olsson, Anders G., Boekholdt, S. Matthijs, Demicco, David A., Szarek, Michael, LaRosa, John C., Pedersen, Terje R., Grundy, Scott M.·2008·Circulation

DOI 10.1161/circulationaha.107.713438

Open this paper in CoChat — free account

Abstract

BACKGROUND: Low-density lipoprotein (LDL) cholesterol is the principal target of lipid-lowering therapy, but recent evidence has suggested more appropriate targets. We compared the relationships of on-treatment levels of LDL cholesterol, non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B, as well as ratios of total/HDL cholesterol, LDL/HDL cholesterol, and apolipoprotein B/A-I, with the occurrence of cardiovascular events in patients receiving statin therapy. METHODS AND RESULTS: A post hoc analysis was performed that combined data from 2 prospective, randomized clinical trials in which 10,001 ("Treating to New Targets") and 8888 ("Incremental Decrease in End Points through Aggressive Lipid Lowering") patients with established coronary heart disease were assigned to usual-dose or high-dose statin treatment. In models with LDL cholesterol, non-HDL cholesterol and apolipoprotein B were positively associated with cardiovascular outcome, whereas a positive relationship with LDL cholesterol was lost. In a model that contained non-HDL cholesterol and apolipoprotein B, neither was significant owing to collinearity. Total/HDL cholesterol ratio and the apolipoprotein B/A-I ratio in particular were each more closely associated with outcome than any of the individual proatherogenic lipoprotein parameters. CONCLUSIONS: In patients receiving statin therapy, on-treatment levels of non-HDL cholesterol and apolipoprotein B were more closely associated with cardiovascular outcome than levels of LDL cholesterol. Inclusion of measurements of the antiatherogenic lipoprotein fraction further strengthened the relationships. These data support the use of non-HDL cholesterol or apolipoprotein B as novel treatment targets for statin therapy. Given the absence of interventions that have been proven to consistently reduce cardiovascular disease risk through raising plasma levels of HDL cholesterol or apolipoprotein A-I, it seems premature to consider the ratio variables as clinically useful.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.107.713438

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Untitled work
(1996) · Cited by 6,884
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citation
Global Burden of Cardiovascular Diseases
Yusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. S. (2001) · Circulation · doi:10.1161/hc4601.099487 · Cited by 3,014
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227
Applied Regression Analysis: A Research Tool
Wisniewski, M., & Rawlings, J. O. (1990) · Journal of the Operational Research Society · doi:10.2307/2583482 · Cited by 1,088
Applied Regression Analysis
Rawlings, J. O., Pantula, S. G., & Dickey, D. A. (1998) · Springer eBooks · doi:10.1007/b98890 · Cited by 1,080
National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
(1994) · Circulation · doi:10.1161/01.cir.89.3.1333 · Cited by 817
Non–HDL Cholesterol, Apolipoproteins A-I and B 100 , Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3
Navab, M., Hama, S. Y., Anantharamaiah, G. M., Hassan, K., Hough, G. P., Watson, A. D., Reddy, S. T., Sevanian, A., Fonarow, G. C., & Fogelman, A. M. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33462-3 · Cited by 663
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women
Ingelsson, E., Schaefer, E. J., Contois, J. H., McNamara, J. R., Sullivan, L., Keyes, M. J., Pencina, M. J., Schoonmaker, C., Wilson, P. W. F., D’Agostino, R. B., et al. (2007) · JAMA · doi:10.1001/jama.298.7.776 · Cited by 608
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Gotto, A. M., Whitney, E. J., Stein, E. A., Shapiro, D. R., Clearfield, M. B., Weis, S. E., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 558
Lipids and risk of coronary heart disease The Framingham Study
Castelli, W. P., Anderson, K. M., Wilson, P. W. F., & Levy, D. A. (1992) · Annals of Epidemiology · doi:10.1016/1047-2797(92)90033-m · Cited by 547
High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00666-9 · Cited by 534
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
Deedwania, P., Barter, P., Carmena, R., Fruchart, J.-C., Grundy, S. M., Haffner, S., Kastelein, J. J., LaRosa, J. C., Schachner, H., Shepherd, J., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69292-1 · Cited by 387
Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee.
(1979) · Circulation · doi:10.1161/01.cir.60.2.427 · Cited by 383
International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material
Marcovina, S. M., Albers, J. J., Henderson, L. O., & Hannon, W. H. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.5.773 · Cited by 342
Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease
Liu, J., Sempos, C. T., Donahue, R. P., Dorn, J., Trevisan, M., & Grundy, S. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.032 · Cited by 277
Self-citation
Plasma very low density lipoproteins contain a single molecule of apolipoprotein B
Elovson, J., Chatterton, J. E., Bell, G. T., Schumaker, V. N., Reuben, M. A., Puppione, D. L., Reeve, J. R., & Young, N. L. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38425-x · Cited by 266
Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial
Simes, R. J., Marschner, I. C., Hunt, D. U., Colquhoun, D. M., SULLIVAN, D. R., Stewart, R., Hague, W. E., KEECH, A. C., Thompson, P., White, H. D., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 250
International federation of clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material
Marcovina, S. M., Albers, J. J., Kennedy, H., Mei, J. V., Henderson, L. O., & Hannon, W. H. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.4.586 · Cited by 243
Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women
Shai, I., Rimm, E. B., Hankinson, S. E., Curhan, G. C., Manson, J. E., Rifai, N., Stampfer, M. J., & Ma, J. (2004) · Circulation · doi:10.1161/01.cir.0000146339.57154.9b · Cited by 236
Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation
Chapman, M. J., Laplaud, P. M., Luc, G., Forgez, P., Bruckert, E., Goulinet, S., & Lagrange, D. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38518-7 · Cited by 216
ATP-binding cassette transporter AI and its role in HDL formation
Lee, J., & Parks, J. S. (2005) · Current Opinion in Lipidology · doi:10.1097/00041433-200502000-00005 · Cited by 187
Non–High-Density Lipoprotein Cholesterol Levels Predict Five-Year Outcome in the Bypass Angioplasty Revascularization Investigation (BARI)
Bittner, V., Hardison, R., Kelsey, S. F., Weiner, B. H., Jacobs, A. K., & Sopko, G. (2002) · Circulation · doi:10.1161/01.cir.0000038496.57570.06 · Cited by 168
Role of the Apolipoprotein B–Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case–Control Analysis in EPIC-Norfolk
van der Steeg, W. A., Boekholdt, S. M., Stein, E. A., El-Harchaoui, K., Stroes, E. S. G., Sandhu, M. S., Wareham, N. J., Jukema, J. W., Luben, R., Zwinderman, A. H., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00007 · Cited by 165
Effects of Folic Acid Supplementation on Hearing in Older Adults
Durga, J., Verhoef, P., Anteunis, L. J. C., Schouten, E. G., & Kok, F. J. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-1-200701020-00003 · Cited by 153
Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B
Benn, M., Nordestgaard, B. G., Jensen, G. B., & Tybjærg‐Hansen, A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255580.73689.8e · Cited by 152
Lecithin : Cholesterol acyltransferase : Effects of substrate composition upon enzyme activity
Fielding, C. J., Shore, V. G., & Fielding, P. E. (1972) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(72)90116-6 · Cited by 147
The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women
Everett, B. M., Kurth, T., Buring, J. E., & Ridker, P. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.030 · Cited by 130
International Federation of Clinical Chemistry Standardization Project for Measurements of Apolipoproteins A-I and B. II. Evaluation and Selection of Candidate Reference Materials
Albers, J. J., Marcovina, S. M., & Kennedy, H. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.5.658 · Cited by 103
Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100
ABATEA, N., Vega, G., & Grundy, S. M. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90187-y · Cited by 76
A Population-Based, Cross-Sectional Comparison of Lipid-Related Indexes for Symptoms of Atherosclerotic Disease
Hsia, S. H., Pan, D., Berookim, P., & Lee, M. L. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.05.024 · Cited by 73
Apolipoprotein-B, Low-Density Lipoprotein Cholesterol, and the Long-Term Risk of Coronary Heart Disease in Men
St‐Pierre, A., Cantin, B., Dagenais, G. R., Després, J., & Lamarche, B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.10.060 · Cited by 65
Non–High-Density Lipoprotein Cholesterol Versus Low-Density Lipoprotein Cholesterol as a Risk Factor for a First Nonfatal Myocardial Infarction
Farwell, W. R., Sesso, H. D., Buring, J. E., & Gaziano, J. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.044 · Cited by 53
Sex and time differences in the associations of non–high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (The Rancho Bernardo Study)
von Mühlen, D. G., Langer, R. D., & Barrett-Connor, E. L. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00319-9 · Cited by 39
Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals
Rallidis, L. S., Pitsavos, C. E., Panagiotakos, D. B., Sinos, L., Stefanadis, C., & Kremastinos, D. T. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.09.022 · Cited by 36
The National Reference System for Cholesterol
Vanderlinde, R. E., Bowers, G. N., Jr., Schaffer, R., & Edwards, G. C. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30644-9 · Cited by 23

Research works printed but not linked: 5

10.1161/circ.104.22.2746 · DOI
10.1161/circ.101.5.477 · DOI
10.1161/circ.105.10.1162 · DOI
10.1161/circ.60.2.312704 · DOI
10.1161/circ.89.3.8124825 · DOI

Sorted by citations

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Gut Microbiome: Profound Implications for Diet and Disease
Hills, R. D., Pontefract, B., Mishcon, H. R., Black, C. A., Sutton, S. C., & Theberge, C. R. (2019) · Nutrients · doi:10.3390/nu11071613 · Cited by 1,143

See all 478

Authors: Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., Szarek, M., LaRosa, J. C., Pedersen, T. R., & Grundy, S. M.
Affiliations: State University of New York (US)
From the Academic Medical Center, University of Amsterdam (J.J.P.K., W.A.v.d.S., S.M.B.), Amsterdam, the Netherlands; Center for Preventive Medicine, Ullevål University Hospital (I.H., T.R.P.), Oslo, Norway; Pfizer Inc (M.G., N.B.C., D.A.D., M.S.), New York, NY; the Heart Research Institute (P.B.), Sydney, Australia; Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine (P.D.), San Francisco, Calif; University Hospital (A.G.O.),...
ORCID: Kastelein, John J.P.
Gaffney, Michael
Cater, Nilo B.
Deedwania, Prakash
Olsson, Anders G.
Boekholdt, S. Matthijs
Demicco, David A.
Szarek, Michael
Pedersen, Terje R.
Grundy, Scott M.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2008-06-10
Volume: 117
Issue: 23
Pages: 3002-3009
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/circulationaha.107.713438
OpenAlex: W1982036768
Cited by: 478
References: 45
Citations by year: 2026: 10 · 2025: 14 · 2024: 16 · 2023: 17 · 2022: 16 · 2021: 24 · 2020: 23 · 2019: 24 · 2018: 23 · 2017: 25 · 2016: 14 · 2015: 32 · 2014: 23 · 2013: 36 · 2012: 31
FWCI: 52.34
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: statin therapy, non-HDL cholesterol, apolipoprotein B, apolipoprotein B/A-I ratio, TC/HDL-C ratio, LDL cholesterol, apolipoprotein A-I, cardiovascular events, coronary artery disease, lipid-lowering targets, lipoprotein ratios
MeSH terms: Aged, Apolipoproteins B, Coronary Disease, Female, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk, Triglycerides, Proportional Hazards Models, Randomized Controlled Trials as Topic, Databases, Factual, Apolipoprotein A-I, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks